Simantov served as head of oncology global medical affairs at Pfizer, where she was responsible for multiple programs including Sutent ® (sunitinib), Inlyta ® (axitinib), Ibrance ® (palbociclib), Bosulif ® (bosutinib) and Xalkori ® (crizotinib). Simantov currently serves as chief medical officer at Gamida Cell, an advanced cell therapy company. Pellizzari received her Bachelor of Arts, cum laude, from the University of Massachusetts, Amherst and her Juris Doctor degree from the University of Colorado, Boulder.ĭr. She previously served as law clerk to the Honorable Reginald Stanton, Assignment Judge for the Superior Court of New Jersey. Pellizzari joined Dendrite from the law firm of Wilentz, Goldman & Spitzer where she specialized in health care transactions and related regulatory matters. As a member of the company’s management team, she led many critical initiatives including the sale of the company to Cegedim S.A. Pellizzari served as Senior Vice President, General Counsel and Secretary of Dendrite International, Inc., a publicly traded company that provided sales effectiveness, promotional and compliance solutions to the pharmaceutical industry. Pellizzari served as Executive Vice President, General Counsel and Secretary of Aegerion Pharmaceuticals, Inc., where she oversaw all legal aspects of the company’s successful IPO and secondary public offering and served as a member of the Executive Management Committee. She brings over 20 years of leadership in the global biopharmaceutical industry. Pellizzari has served as Science 37’s Chief Legal Officer since 2021, previously serving at Insmed since 2013, most recently as Chief Legal Officer. In 2021, Geoff transitioned from CMO into a Senior Advisor role with BioMarin, and remained active with the company until mid 2022. In 2016, Geoff became CMO at BioMarin, managing an active portfolio of clinical development programs, including the development and approval of Brineura, Palynziq, phase 3 development of BMN 270, a leading gene therapy for hemophilia A, BMN 111, a groundbreaking treatment for achondroplasia, and BMN 307, a gene therapy for PKU. He managed the pre-clinical development of several genome editing IND candidates both in vivo and ex vivo in T cells and hematopoietic stem cells, and an AAV cDNA FVIII gene therapy for hemophilia A, all now in clinical trials. Subsequently, 2002-2009, he was SVP of Development at Medarex Inc, where he was responsible for the foundational clinical development of the breakthrough cancer immunotherapy checkpoint inhibitors Yervoy (Phase 1 through Phase 3) and Opdivo (Phase 1) culminating in the acquisition of Medarex by Bristol-Myers Squibb and the award, in 2018, of the Nobel Prize for Medicine and Physiology related to these programs.įrom 2011-2016 Geoff was EVP R&D at Sangamo BioSciences, a zinc finger genome editing and gene therapy company. As a VP at Novartis 1996-2002, he managed, successively, a clinical development therapeutic area, US Medical Affairs, and Global Project and Portfolio Management, with significant involvement in the Foradil and Xolair programs. His first successful drug development success was at SmithKline Beecham with the approval of Augmentin BID in 1996 for adults and children for all indications. Geoff Nichol, M.B., Ch.B., M.B.A., has nearly 30 years’ experience in drug development. from DePauw University.įormer Chief Medical Officer and Senior Advisor, BioMarin Previous to Genzyme, he held business development and sales and marketing positions at Repligen and Bristol-Myers. Mike also spent two years with Genzyme’s diagnostic products and services division. Mr. Raab was also instrumental in the worldwide launch of Genzyme’s therapies for Gaucher disease, Ceredase and Cerezyme.
In this position, he launched and oversaw the sales growth of sevelamer, the leading phosphate binder for the treatment of hyperphosphatemia, with over $1.0 billion in worldwide sales in 2013. He was senior vice president, therapeutics and general manager of the renal division at Genzyme Corporation, a Sanofi company. Prior to joining NEA in 2002, Mr. Raab spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. Before Ardelyx, he was a partner at New Enterprise Associates (NEA), one of the world’s largest and most successful venture capital firms, where he specialized in healthcare investments focusing on the biotechnology and pharmaceutical sectors. Mr. Raab has served as Ardelyx’s president and chief executive officer since March 2009.
0 kommentar(er)
